142 related articles for article (PubMed ID: 9335081)
21. Effects of CCK-tetrapeptide in patients with social phobia and obsessive-compulsive disorder.
Katzman MA; Koszycki D; Bradwejn J
Depress Anxiety; 2004; 20(2):51-8. PubMed ID: 15390214
[TBL] [Abstract][Full Text] [Related]
22. Sensitivity to cholecystokinin-tetrapeptide in major depression.
Koszycki D; Copen J; Bradwejn J
J Affect Disord; 2004 Jun; 80(2-3):285-90. PubMed ID: 15207943
[TBL] [Abstract][Full Text] [Related]
23. The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers.
Maron E; Tõru I; Vasar V; Shlik J
J Psychopharmacol; 2004 Jun; 18(2):194-9. PubMed ID: 15260907
[TBL] [Abstract][Full Text] [Related]
24. Acute shift in glutamate concentrations following experimentally induced panic with cholecystokinin tetrapeptide--a 3T-MRS study in healthy subjects.
Zwanzger P; Zavorotnyy M; Gencheva E; Diemer J; Kugel H; Heindel W; Ruland T; Ohrmann P; Arolt V; Domschke K; Pfleiderer B
Neuropsychopharmacology; 2013 Aug; 38(9):1648-54. PubMed ID: 23463151
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study.
Eser D; Schüle C; Baghai T; Floesser A; Krebs-Brown A; Enunwa M; de la Motte S; Engel R; Kucher K; Rupprecht R
Psychopharmacology (Berl); 2007 Jul; 192(4):479-87. PubMed ID: 17318504
[TBL] [Abstract][Full Text] [Related]
26. Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram.
Tõru I; Shlik J; Maron E; Vasar V; Nutt DJ
Psychopharmacology (Berl); 2006 May; 186(1):107-12. PubMed ID: 16541242
[TBL] [Abstract][Full Text] [Related]
27. Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients.
Charney DS; Woods SW; Krystal JH; Nagy LM; Heninger GR
Acta Psychiatr Scand; 1992 Oct; 86(4):273-82. PubMed ID: 1333719
[TBL] [Abstract][Full Text] [Related]
28. Effects of flumazenil on cholecystokinin-tetrapeptide-induced panic symptoms in healthy volunteers.
Bradwejn J; Koszycki D; Couëtoux du Tertre A; Paradis M; Bourin M
Psychopharmacology (Berl); 1994 Mar; 114(2):257-61. PubMed ID: 7838917
[TBL] [Abstract][Full Text] [Related]
29. Effects of cholecystokinin tetrapeptide on respiratory function in healthy volunteers.
Bradwejn J; LeGrand JM; Koszycki D; Bates JH; Bourin M
Am J Psychiatry; 1998 Feb; 155(2):280-2. PubMed ID: 9464212
[TBL] [Abstract][Full Text] [Related]
30. Dose ranging study of the effects of cholecystokinin in healthy volunteers.
Bradwejn J; Koszycki D; Bourin M
J Psychiatry Neurosci; 1991 Jul; 16(2):91-5. PubMed ID: 1911739
[TBL] [Abstract][Full Text] [Related]
31. Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients.
van Megen HJ; Westenberg HG; den Boer JA; Haigh JR; Traub M
Psychopharmacology (Berl); 1994 Apr; 114(3):449-55. PubMed ID: 7855203
[TBL] [Abstract][Full Text] [Related]
32. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings.
Bradwejn J; Koszycki D; Shriqui C
Arch Gen Psychiatry; 1991 Jul; 48(7):603-10. PubMed ID: 2069490
[TBL] [Abstract][Full Text] [Related]
33. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder.
Bradwejn J; Koszycki D; Couëtoux du Tertre A; van Megen H; den Boer J; Westenberg H
Arch Gen Psychiatry; 1994 Jun; 51(6):486-93. PubMed ID: 8192551
[TBL] [Abstract][Full Text] [Related]
34. The panic-inducing properties of the cholecystokinin tetrapeptide CCK4 in patients with panic disorder.
van Megen HJ; Westenberg HG; Den Boer JA; Kahn RS
Eur Neuropsychopharmacol; 1996 Aug; 6(3):187-94. PubMed ID: 8880078
[TBL] [Abstract][Full Text] [Related]
35. Alpha 2-adrenergic receptor sensitivity in panic disorder: II. Cortisol response to clonidine stimulation in panic disorder.
Brambilla F; Bellodi L; Arancio C; Nobile P; Perna G
Psychoneuroendocrinology; 1995; 20(1):11-9. PubMed ID: 7838899
[TBL] [Abstract][Full Text] [Related]
36. Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition.
Otte C; Moritz S; Yassouridis A; Koop M; Madrischewski AM; Wiedemann K; Kellner M
Neuropsychopharmacology; 2007 Jan; 32(1):232-8. PubMed ID: 17035932
[TBL] [Abstract][Full Text] [Related]
37. Alpha 2-adrenergic receptor sensitivity in panic disorder: I. GH response to GHRH and clonidine stimulation in panic disorder.
Brambilla F; Perna G; Garberi A; Nobile P; Bellodi L
Psychoneuroendocrinology; 1995; 20(1):1-9. PubMed ID: 7838898
[TBL] [Abstract][Full Text] [Related]
38. Atrial natriuretic hormone in lactate-induced panic attacks: mode of release and endocrine and pathophysiological consequences.
Kellner M; Knaudt K; Jahn H; Holsboer F; Wiedemann K
J Psychiatr Res; 1998; 32(1):37-48. PubMed ID: 9693999
[TBL] [Abstract][Full Text] [Related]
39. Growth hormone response to intravenous clonidine in social phobia: comparison to patients with panic disorder and healthy volunteers.
Tancer ME; Stein MB; Uhde TW
Biol Psychiatry; 1993 Nov; 34(9):591-5. PubMed ID: 8292687
[TBL] [Abstract][Full Text] [Related]
40. Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings.
Bradwejn J; Koszycki D; Payeur R; Bourin M; Borthwick H
Am J Psychiatry; 1992 Jul; 149(7):962-4. PubMed ID: 1609879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
